<DOC>
	<DOCNO>NCT02101593</DOCNO>
	<brief_summary>Assessment safety tolerability ADI-PEG 20 combination sorafenib advance Hepatocellular Carcinoma ( HCC ) .</brief_summary>
	<brief_title>Ph 1 Trial ADI PEG 20 Plus Sorafenib Treat Patients With Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>1 . Prior diagnosis HCC confirm histologically . 2 . HCC tissue either archive specimen new biopsy sufficient amount quality available IHC determination ASS status , biomarkers , perform retrospectively . Subjects tissue available would require biopsy . 3 . No prior treatment systemic chemotherapy ( except note exclusion criterion # 10 ) . 4 . Measurable disease use RECIST 1.1 criterion ( Appendix A ) . At least 1 measurable lesion must present . Subjects receive localregional therapy ( limited ) chemoembolization , embolization , cryoablation , hepatic artery therapy , percutaneous ethanol injection , radiation therapy , radiofrequency ablation surgery eligible , provide either target lesion treated local therapy and/or target lesion ( ) within field local regional therapy show increase ≥ 20 % size . Localregional therapy must complete least 4 week prior baseline CT scan . Local therapy include chemoembolization count prior systemic therapy . 5 . Cirrhotic status ChildPugh grade A. ChildPugh status determine base clinical finding laboratory data screen period ( Appendix B ) . Subjects anticoagulant receive 1 point INR status , presume &lt; 1.7 baseline PT/INR . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 ( Appendix C ) . 7 . Expected survival least 3 month . 8 . Age ≥ 18 year . 1 . Candidate potential curative therapy ( i.e. , resection transplantation ) . 2 . Prior allograft transplantation include liver transplantation . 3 . Serious infection require treatment systemically administer antibiotic time study entrance , infection require systemic antibiotic therapy within 7 day prior first dose study treatment . 4 . Pregnancy lactation . 5 . Expected noncompliance . 6 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure ( New York Heart Association Class III IV ; Appendix D ) , unstable angina pectoris , cardiac arrhythmia , psychiatric illness social situation would limit compliance study requirement . 7 . Subjects fully recover toxicity associate previous HCC locoregional therapy . 8 . Subjects history another primary cancer , exception : ) curatively resect nonmelanoma skin cancer ; b ) curatively treated cervical carcinoma situ ; c ) primary solid tumor know active disease present opinion investigator affect patient outcome set current HCC diagnosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>argininosuccinate synthetase</keyword>
	<keyword>arginine</keyword>
	<keyword>arginine deiminase</keyword>
</DOC>